Literature DB >> 20406635

KU812 cells provide a novel in vitro model of the human IL-33/ST2L axis: functional responses and identification of signaling pathways.

Nadine Tare1, Hongli Li, Andrew Morschauser, Javier Cote-Sierra, Grace Ju, Louis Renzetti, Tai-An Lin.   

Abstract

Activation of interleukin-1 family receptor ST2L by its ligand interleukin-33 (IL-33) is an important component in inflammatory responses. Peripheral blood basophils, recognized as major effector cells in allergic inflammation that play a role in both innate and adaptive immunity, are activated by IL-33 through ST2L. However, studies are challenging due to the paucity of this cell population, representing less than 1% of peripheral blood leukocytes. We identified a basophil-like chronic myelogenous leukemia cell line, KU812, that constitutively expresses ST2L and demonstrates functional responses to IL-33 stimulation. IL-33 induced production of multiple inflammatory mediators in KU812 cells that were blocked by anti-ST2L and anti-IL-33 antibodies. The interaction of IL-33 and ST2L activated NF-kappaB, JNK, and p38 MAPK, but not ERK1/2 signaling pathways. Studies using pharmacological inhibitors to IKK-2 and MAP kinases revealed that one of the functional responses, IL-33-induced IL-13 production, was regulated through NF-kappaB, but not JNK or p38 MAPK signaling. The requirement of NF-kappaB was confirmed by IKK-2 knockdown using shRNA. KU812 represents the first human cell line-based in vitro model of the IL-33/ST2L axis and provides a valuable tool to aid in understanding the mechanism and significance of IL-33 and ST2L interaction and function. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406635     DOI: 10.1016/j.yexcr.2010.04.007

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  Quantitative phosphoproteomic analysis of IL-33-mediated signaling.

Authors:  Sneha M Pinto; Raja Sekhar Nirujogi; Pamela Leal Rojas; Arun H Patil; Srikanth S Manda; Yashwanth Subbannayya; Juan Carlos Roa; Aditi Chatterjee; T S Keshava Prasad; Akhilesh Pandey
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

Review 2.  Interleukin-33 biology with potential insights into human diseases.

Authors:  Gaby Palmer; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2011-04-26       Impact factor: 20.543

3.  IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G.

Authors:  Emma Lefrançais; Stephane Roga; Violette Gautier; Anne Gonzalez-de-Peredo; Bernard Monsarrat; Jean-Philippe Girard; Corinne Cayrol
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

4.  Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.

Authors:  Jennifer E Ho; Wei-Yu Chen; Ming-Huei Chen; Martin G Larson; Elizabeth L McCabe; Susan Cheng; Anahita Ghorbani; Erin Coglianese; Valur Emilsson; Andrew D Johnson; Stefan Walter; Nora Franceschini; Christopher J O'Donnell; Abbas Dehghan; Chen Lu; Daniel Levy; Christopher Newton-Cheh; Honghuang Lin; Janine F Felix; Eric R Schreiter; Ramachandran S Vasan; James L Januzzi; Richard T Lee; Thomas J Wang
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

5.  Effects of interleukin-33 on cardiac fibroblast gene expression and activity.

Authors:  Jinyu Zhu; Wayne Carver
Journal:  Cytokine       Date:  2012-03-23       Impact factor: 3.861

Review 6.  Regulation of Type 2 Immunity in Myocardial Infarction.

Authors:  Jun-Yan Xu; Yu-Yan Xiong; Xiao-Tong Lu; Yue-Jin Yang
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

7.  The anti-atherogenic cytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1, -4 and -5 in human macrophages: Requirement of extracellular signal-regulated kinase, c-Jun N-terminal kinase and phosphoinositide 3-kinase signaling pathways.

Authors:  Tim G Ashlin; Melanie L Buckley; Rebecca C Salter; Jason L Johnson; Alvin P L Kwan; Dipak P Ramji
Journal:  Int J Biochem Cell Biol       Date:  2013-11-22       Impact factor: 5.085

Review 8.  The Role of IL-33/ST2 Pathway in Tumorigenesis.

Authors:  Kristen M Larsen; Maydelis Karla Minaya; Vivek Vaish; Maria Marjorette O Peña
Journal:  Int J Mol Sci       Date:  2018-09-09       Impact factor: 5.923

Review 9.  The ST2/Interleukin-33 Axis in Hematologic Malignancies: The IL-33 Paradox.

Authors:  Alessandro Allegra; Vanessa Innao; Gennaro Tartarisco; Giovanni Pioggia; Marco Casciaro; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-10-22       Impact factor: 5.923

10.  Cytokines Stimulated by IL-33 in Human Skin Mast Cells: Involvement of NF-κB and p38 at Distinct Levels and Potent Co-Operation with FcεRI and MRGPRX2.

Authors:  Kristin Franke; Zhao Wang; Torsten Zuberbier; Magda Babina
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.